Results 21 to 30 of about 3,132 (216)

Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore [PDF]

Ophthalmology and Therapy
Introduction To evaluate visual and anatomical outcomes after switching to faricimab in Singaporean patients with diabetic macular edema (DME) previously treated with other anti‑vascular endothelial growth factor (VEGF) agents or therapies.
Kanae Fukutsu, Rose Ann Goh, Fang Zheng, Charles Ong, Anna C. S. Tan, Gemmy C. M. Cheung, SNEC Retina Research Group, Gavin S. W. Tan   +7 more
doaj   +2 more sources

Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review [PDF]

International Journal of Retina and Vitreous
Background To systematically review the real-world outcomes of intravitreal faricimab treatment in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy and safety in clinical settings. This study was conducted due to
Nasratullah Nasimi, Safiullah Nasimi, Jakob Grauslund, Anna Stage Vergmann, Yousif Subhi   +4 more
doaj   +2 more sources

Intravitreal faricimab pharmacokinetics assessed by PET imaging in a neovascular Age-related Macular Degeneration rat model [PDF]

International Journal of Pharmaceutics: X
Age-related Macular Degeneration (AMD) is the leading cause of blindness in the elderly, with its neovascular form characterised by abnormal vessel growth.
Xurxo García-Otero, Andrea Cuartero-Martínez, Patricia Fernández-Robredo, Soraya Groba-de Antas, Noemí Gómez-Lado, Francisco J. Otero-Espinar, María Hernández, Jaione Bezunartea, Alfredo García-Layana, Sergio Recalde, Pablo Aguiar, Anxo Fernández-Ferreiro   +11 more
doaj   +2 more sources

Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients.

American journal of ophthalmology-glaucoma
PURPOSE To describe the patient characteristics and clinical course of severe intraocular inflammation (IOI) following intravitreal injection (IVT) of faricimab. DESIGN Retrospective case series. METHODS Case series at a single French academic center
I. Ben Ghezala, P. Gabrielle, Maxime Sibert, Laure-Anne Steinberg, A. Dautriche, Louis Arnould, C. Creuzot-Garcher   +6 more
semanticscholar   +2 more sources

Exudative retinopathy from retinal vasoproliferative tumor refractory to aflibercept treated with faricimab-svoa [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report a case of exudative retinopathy secondary to retinal vasoproliferative tumor (RVPT) refractory to aflibercept treated with faricimab-svoa (faricimab).
Naveen Karthik, Syeda Fatima Abid, Yuxi Zheng, Miguel Materin, Xi Chen   +4 more
doaj   +2 more sources

Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US [PDF]

Ophthalmology and Therapy
This is a summary of the original article “Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US”.
Andreas Kuznik, Anna Coughlan, Amy Pinsent, Hector Toro-Diaz, Steven Sherman, Nimesh A. Patel   +5 more
doaj   +2 more sources

Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration.

Ophthalmic Surgery Lasers and Imaging Retina
BACKGROUND AND OBJECTIVE This study assessed treatment patterns and early outcomes among patients with neovascular age-related macular degeneration (nAMD) initiating faricimab in routine clinical practice in the United States.
Ferhina S. Ali, D. Tabano, Durga S. Borkar, Theodore Leng, Vincent Garmo, Ayesha Ahmed, Rachel Myers, Jacqueline K. Shaia, Giulio Barteselli, Rishi P. Singh   +9 more
semanticscholar   +2 more sources

Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials

Ophthalmology and Therapy, 2023
Introduction This review aims to assess the efficacy, durability and safety of faricimab—a dual vascular endothelial growth factor and angiopoietin 2 inhibitor—in patients with neovascular age-related macular degeneration (nAMD) and diabetic macula ...
Helene O. Larsen, Jakob Grauslund, Anna S. Vergmann   +2 more
doaj   +1 more source

Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties

International Journal of Retina and Vitreous, 2023
Background Intravitreal injection (IVI) of antibody biologics is a key treatment approach in ophthalmology. Pharmaceutical compounding and storage of prefilled syringes for IVI must take place without impairing the structure and function of the biologics.
Øystein Kalsnes Jørstad, Stian Foss, Torleif Tollefsrud Gjølberg, Simone Mester, Mari Nyquist-Andersen, Magne Sand Sivertsen, Dag Fossum, Espen Gleditsch, Morten Carstens Moe, Jan Terje Andersen   +9 more
doaj   +1 more source

Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration

Scientific Reports, 2023
Though vascular endothelial growth factors (VEGF) and other proangiogenic factors, such as angiopoietins (Ang), may be involved in the development of neovascular age-related macular degeneration (nvAMD), only drugs that inhibit the VEGF family are ...
Ryosuke Tamiya, Masayuki Hata, Asako Tanaka, Memiri Tsuchikawa, Naoko Ueda-Arakawa, Hiroshi Tamura, Manabu Miyata, Ayako Takahashi, Ai Kido, Yuki Muraoka, Masahiro Miyake, Sotaro Ooto, Akitaka Tsujikawa   +12 more
doaj   +1 more source